Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

NCT ID NCT02143635
Title Study to Determine and Evaluate a Safe and Tolerated Dose of HDM201 in Patients With Selected Advanced Tumors That Are TP53wt
Recruitment Completed
Gender both
Phase Phase I
Variant Requirements Yes
Sponsors Novartis Pharmaceuticals
Indications
Therapies
Age Groups: adult
Covered Countries USA | NLD | FRA | ESP | DEU

Facility Status City State Zip Country Details
Dana Farber Cancer Institute SC-6 Boston Massachusetts 02215 United States Details
Memorial Sloan Kettering Onc. Dep New York New York 10017 United States Details
Novartis Investigative Site Lyon Cedex 69373 France Details
Novartis Investigative Site Paris 75010 France Details
Novartis Investigative Site Essen 45147 Germany Details
Novartis Investigative Site Frankfurt 60590 Germany Details
Novartis Investigative Site Wuerzburg 97080 Germany Details
Novartis Investigative Site Kobe-shi Hyogo 650-0017 Japan Details
Novartis Investigative Site Chuo ku Tokyo 104 0045 Japan Details
Novartis Investigative Site Amsterdam 1066 CX Netherlands Details
Novartis Investigative Site Utrecht 3584CX Netherlands Details
Novartis Investigative Site Singapore 169610 Singapore Details
Novartis Investigative Site Barcelona Catalunya 08035 Spain Details
Novartis Investigative Site Barcelona Catalunya 08036 Spain Details
Novartis Investigative Site Taipei Taiwan ROC 10041 Taiwan Details
*Shaded cells indicate that there was no data available from clincialtrials.gov for the field